Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial - PubMed
4 hours ago
- #benralizumab
- #hypereosinophilic syndrome
- #clinical trial
- Benralizumab, an anti-IL-5 receptor α antibody, was evaluated in the NATRON phase 3 trial for treating FIP1L1::PDGFRA-negative hypereosinophilic syndrome (HES).
- The randomized, double-blind, placebo-controlled study involved 133 patients receiving benralizumab 30 mg every 4 weeks or placebo for 24 weeks alongside background therapy.
- Benralizumab significantly reduced the risk of first HES flare compared to placebo, with a hazard ratio of 0.35 (95% CI 0.18 to 0.69, P = 0.0024).
- Adverse events occurred in 64.2% of benralizumab-treated patients and 66.7% of placebo-treated patients, with safety consistent with benralizumab's known profile.
- The results demonstrate the efficacy and safety of add-on benralizumab for HES treatment, with many authors reporting financial ties to AstraZeneca and other pharmaceutical companies.